Tumor-suppressing roles of miR-214 and miR-218 in breast cancer
- Authors:
- Published online on: April 15, 2016 https://doi.org/10.3892/or.2016.4749
- Pages: 3178-3184
-
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Breast cancer is one of the most common malignancies among females (1), which can occur in humans and other mammals, and most cases are women (2). Over 1 million persons are diagnosed with breast cancer each year (3). Similarly to other cancers, carcinogenesis of breast cancer is a complex process. Although mortality rate of breast cancer has been observably reduced, metastatic breast cancer still remains puzzling (4). The mechanisms of carcinogenesis and metastasis need to be better clarified.
MicroRNA (miRNA) is a class endogenous non-coding single-stranded RNA. As circulating marker, miRNA is being studied extensively (5,6). miRNAs are able to downregulate approximately 1/3 human genes by binding to 3′-untranslated region (3′-UTR) of target mRNA (5,7). miRNAs are involved in many biological processes, such as cell proliferation, apoptosis, migration and carcinogenesis (8–11). Many miRNAs are also involved in carcinogenesis and development of breast cancer (9,10). It has been shown that miR-200c, miR-206, miR-335, miR-494 and miR-125b are downregulated in breast cancer tissues, suggesting that they may play tumor suppressor roles (12–16). As oncogenes of breast cancer, miR-155, miR-21, miR-210, miR-373 and miR-10b are upregulated in patients with breast cancer (17–20). The miR-214 is decreased in breast cancer (21), and miR-218 is also known as a tumor suppressor in prostate cancer, hepatocellular carcinoma and glioblastoma (22–24), but the mechanisms of both miR-214 and miR-218 are unclear.
In the present study, we investigate the expression of miR-214 and miR-218 in breast cancer and adjacent tissues, and analyzed the correlations in miR-214 and miR-218 expression and the clinicopathological characteristics. The effects of miR-214 or miR-218 on cell proliferation, apoptosis and cell cycle were also determined in vitro. Our results may provide new biomarkers for diagnosis, prognosis and therapy, and be helpful to clarify the mechanisms of post-transcription regulation in breast cancer.
Materials and methods
Clinical samples
Forty-nine breast cancer tissues and their paired adjacent tissue samples, which were diagnosed by pathological surgical resection, were collected between 2013 and 2015 at The First Hospital of Hebei Medical University (Shijiazhuang, China). The tissues were frozen in liquid nitrogen at −80°C immediately until use. Breast cancer patients who had undergone chemotherapy or radiation therapy before surgery were excluded.
Ethics statements
Permission to use human tissue samples for research purposes was approved by the Biomedical Ethics Committee of Hebei Medical University, Shijiazhuang, Hebei, China. All patients were female and consented to participate in the present study.
Cell line and transfection
Breast cancer cell line MCF-7 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA), cultured in RPMI-1640 containing 10% fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 mg/ml of streptomycin (Gibco, Grand Island, NY, USA) in a humidified atmosphere containing 5% CO2 at 37°C. For transfection, cells were seeded and cultured for 24 h in 12-well plates. According to the manufacturer's instructions, cells were transfected with miR-214 mimic, miR-218 mimic or negative control, respectively, by Lipofectamine 2000 (Invitrogen Life Technologies, Grand Island, NY, USA) in serum-free medium. Six hours after the transfection, the complete medium was changed and maintained for 48 h at 37°C in 5% CO2. The mimics of miR-214, miR-218 and negative control were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China).
Real-time reverse transcription polymerase chain reaction (real-time RT-PCR)
Total RNA was extracted from breast cancer tissues, adjacent tissues and MCF-7 cells by TRIzol reagent (Invitrogen), according to the manufacturer's instructions. Reverse transcription PCR and real-time PCR were performed with TaqMan microRNA Reverse Transcription kit and TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA, respectively) following standard protocol. U6 was used as an endogenous control to normalize variance. The primers of miR-214, miR-218 and U6 were purchased from Applied Biosystems. The fold changes were calculated via relative quantification (2−ΔCT).
Cell proliferation assay
Cell proliferation was determined by the Cell Counting kit-8 assay (CCK-8; Dojindo Molecular Technologies, Inc., Beijing, China). MCF-7 cells (1,000 cells/well) were cultured in 96-well plates. After incubation, 10 µl of the CCK-8 solution was added to each well of the plate, and incubated for 1 h in the incubator, and the absorbance was measured at 450 nm using a microplate reader according to the CCK-8 kit manufacturer's instructions.
Flow cytometry
The effects of miR-214 and miR-218 on breast cancer cell apoptosis and cell cycle were examined by flow cytometry (BD Biosciences, Mansfield, MA, USA). In brief, MCF-7 cells were transfected with miR-214 mimic, miR-218 mimic or negative control for 48 h, the cells were completely collected including apoptotic cells in culture medium, and washed twice with cold PBS. The cell apoptosis were analyzed by Annexin V-FITC detection kit (Neobioscience Technology, Shenzhen, China) according to the manufacturer's protocol. For determining the cell cycle, the cells were transfected for 48 h, washed twice with PBS, treated with trypsin, and fixed with 75% ethanol overnight at −20°C, and incubated with 100 mg/ml RNase A and 50 mg/ml propidium iodide (PI) at room temperature for 30 min. The percentage of the G0/G1, S and G2/M populations were evaluated in each group. The data were analyzed by CellQuest Pro software. Each experiment was performed in triplicate.
Wound-healing assay
MCF-7 cells were grown to confluence. A wound was made by scraping with a conventional pipette tip across the confluence cell layer, and washed with PBS twice. Forty-eight hours after scraping, migration was determined, using the ImageJ, as a percentage of healing area relative to the initial wound area.
Statistical analysis
Data were processed by the SPSS Graduate Pack 13.0, GraphPad 5 software or the Student's t-test. P<0.05 was considered to be statistically significant.
Results
miR-214 and miR-218 are downregulated in breast cancer tissues
To assess the effects of miR-214 and miR-218 on breast cancer development, we first evaluated miR-214 and miR-218 expression levels in breast cancer and adjacent cancer tissues by real-time RT-PCR. The expression of miR-214 and miR-218 was significantly downregulated in breast cancer tissues compared with matching adjacent tissues (P<0.01, respectively; Fig. 1).
Correlation of miR-214 or miR-218 expression with clinicopathological data
We further evaluated the correlation of miR-214 or miR-218 expression and the clinicopathological factors, including age, tumor size, lymph node metastasis, clinical stage, estrogen receptor (ER), progesterone receptor (PR), epidermal factor receptor-2 (HER-2), p53 and Ki-67. ER, PR, HER-2, p53 and Ki-67 were detected by immunohistochemistry, respectively. When the number of stained cells was >10% in one field, it was defined as positive. We found that miR-214 and miR-218 expression was negatively associated with Ki-67 expression (Fig. 2A and C; P=0.025, 0.018, respectively), and the expression of PR was positively associated with miR-218 (Fig. 2D; P=0.027), but not miR-214 (Fig. 2B; P=0.4). There was no correlation between the miR-214 or miR-218 expression level with age, tumor size, lymph node metastasis, stage, ER, HER-2 and p53 (Table I).
 | Table ICorrelations of miR-214 and miR-218 expression and the clinicopathological characteristics of breast cancer patients. |
Overexpression of miR-214 and miR-218 inhibits the breast cancer cell proliferation
To test the biological function of miR-214 and miR-218, the miR-214 mimic, miR-218 mimic and negative controls were purchase from Applied Biosystems. The overexpression of miR-214 or miR-218 was carried out in MCF-7 cells by transfection with miR-214 mimic or miR-218 mimic, respectively. The expression of miR-214 (Fig. 3A) and miR-218 (Fig. 3B) were detected by real-time RT PCR in transfected cells. To investigate the effect of miR-214 and miR-218 on cell proliferation, cell proliferation assay were performed by the Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies), according to the manufacturer's instructions. After transfection with miR-214 and miR-218 mimic, respectively, the cells proliferation was significantly reduced compared to negative control transfected MCF-7 cells (Fig. 3C). The data showed that miR-214 and miR-218 were able to regulate cell proliferation of breast cancer.
Overexpression of miR-214 and miR-218 perturbs breast cancer cell cycle
The cell cycles were analyzed by flow cytometry (BD Biosciences) after staining with propidium iodide (PI). The percentage of cells in the G0/G1, S and G2/M phases was, respectively, evaluated under the negative control (Fig. 4A), miR-214 (Fig. 4B) or miR-218 (Fig. 4C) mimic transfection. As shown in Fig. 4D, the percentage of S phase cells was significantly decreased in miR-214 overexpressed MCF-7 cells comparing with control cells (13.21±1.38 vs. 17.20±0.39, P=0.0298), accompanied by an increase of G0/G1 phase cell ratio (79.78±2.29 vs. 76.08±0.02, P=0.11, no-statistical significance). The percentage of G0/G1 phase cells was significantly reduced in miR-218 overexpressed MCF-7 cells compared with control cells (65.74±1.40 vs. 76.08±0.02, P=0.006; Fig. 4D), and a marked increase of the cell ratio of S phase was observed in the miR-218 mimic transfected cells, compared to control cells (27.62±0.98 vs. 17.20±0.39, P=0.0009; Fig. 4D). The results confirmed that miR-214 and miR-218 disturbed the breast cancer cell cycle.
Overexpression of miR-214 and miR-218 induced early breast cancer cells apoptosis
The cells were seeded into 6-well plates and transfected with negative control, miR-214 or miR-218 mimic, and cell apoptosis were analyzed by Annexin V-FITC detection kit according to the manufacturer's protocol. Representative results of negative control (Fig. 5A), miR-214 mimic (Fig. 5B), and miR-218 mimic (Fig. 5C) are shown, respectively. The ratio of early apoptosis was analyzed by flow cytometry (Fig. 5D). The results confirmed that cell apoptosis was significantly augmented in the miR-214 or miR-218 mimic transfected cells. These results verified that miR-214 and miR-218 were able to mediate breast cancer cell apoptosis.
Overexpression of miR-214 and miR-218 reduced breast cancer cell migration
Cell migration was tested by wound-healing assay. Cell migration was decreased in miR-214 mimic (28.02±0.89 vs. 44.38±3.71%, P=0.013) and miR-218 (27.07±5.75 vs. 44.38±3.71%, P=0.017) mimic treated cells compared with negative control transfected cells (Fig. 6A and B). These results demonstrated that overexpression of miR-214 or miR-218 could inhibit breast cancer cell migration.
Discussion
The expression of miR-214 has been verified downregulated in human cervical cancer (25–27), pancreatic cancer (28), hepatocellular carcinoma (29,30) and breast cancer (28) and miR-218 expression is also reduced in oral squamous cell carcinoma, nasopharyngeal carcinoma, and bladder cancer cells (31–34). However, the molecular biological functions of miR-214 and miR-218 have not clarified in breast cancer. In the present study, we comprehensively evaluated the biological functions of miR-214 and miR-218 in breast cancer. The results indicated that miR-214 and miR-218 function as tumor suppressor genes in breast cancer.
In particular, expression of miR-214 and miR-218 was reduced in human breast cancer tissues, and miR-214 or miR-218 expression is negatively associated with Ki-67, a cellular marker of tumor cells proliferation (Fig. 2). In vitro, we also validated that miR-214 and miR-218 negatively mediated MCF-7 cell proliferation and interfered with cell cycle (Figs. 3 and 4). Previous studies have already demonstrated that the miR-214 could suppress oncogenesis of bladder cancer by targeting the p53 and DNA damage-regulated protein 1 (PDRG1) (35), inhibit the progression of hepatocellular carcinoma by regulating β-catenin (36,37), also mediating cell proliferation by targeting ERK (38), mitochondrial transcription factor A (TFAM) (39) and ADP-ribosylation factor-like protein 2 (ARL2) (40). The miR-218 suppresses lung cancer and cardiac myxoma cell growth by reducing myocyte enhancer factor 2D (MEF2D) (41,42), inhibits glioma cells proliferation by inactivation of cyclin D1 (43) pathway and directly target E2F2 (24), reduces bladder cancer and esophageal squamous cells proliferation by targeting BMI-1 (34,44). The above evidence supports our conclusion.
Our results also prove that the miR-214 and miR-218 promote early apoptosis of breast cancer cells (Fig. 5). The effects of miR-214 are inconsistent, but some studies above confirm that overexpression of miR-214 can promote apoptosis and the sensitivity of cisplatin (45,46). In addition, miR-218 promoted prostate cancer cells apoptosis by repression tumor protein D52 (22), enhanced chemotherapy sensitivity by targeting BIRC5 and breast cancer 1 (47,48), sensitized glioma cells to apoptosis by regulating NF-κB (49). Our results, and the previous results imply that miR-214 and miR-218 could protect against tumorigenesis by inducing apoptosis.
The effects of miR-214 and miR-218 on breast cancer cell migration are shown in Fig. 6. Some previous research supports our results, there is evidence to prove that miR-214 could directly bind to the 3′-UTR of vascular endothelial growth factor (VEGF) (50), the 3′-UTR of polypeptide GalNAc transferase 7 (26) and the 3′-UTR of PTEN (51). The miR-218 also suppresses the cancer cell migration or invasion by downregulating high mobility group box 1, LIM and SH3 protein 1, T-cell lymphoma invasion and metastasis 1 (TIAM1), matrix metalloproteinase 2 and 9 (52–54). These genes induced cell migration or invasion. Other targets of miR-214 and miR-218 will be analyzed in the following study. Interestingly, the expression of miR-214 and miR-218 are positively associated with PR (55), although there is no statistic difference between miR-214 and PR expression. Many investigators consider that PR promotes cell migration, but some investigators still assert that progesterone or PR could exert cell migration inhibitory action (56–59). Our results suggest that PR may, via mediating miR-214 or miR-218, inhibit breast cancer migration.
In conclusion, our results show that miR-214 and miR-218 expression are decreased in breast cancer tissues. Overexpression of miR-214 or miR-218 could suppress cell proliferation and migration, disturb the cell cycle and induce cell apoptosis in vitro. Our findings suggest that miR-214 and miR-218, as tumor suppressors, could play important roles in development of breast cancer, and may be potential therapeutic targets for breast cancer. Therefore, further research on miR-214 and miR-218 functional mechanisms in breast cancer is required.
Acknowledgments
The present study was supported by the Science and Technology Support Project of Hebei, China (no. 14277755D).
References
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fentiman IS, Fourquet A and Hortobagyi GN: Male breast cancer. Lancet. 367:595–604. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kroemer G, Senovilla L, Galluzzi L, André F and Zitvogel L: Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 21:1128–1138. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J and Weigel RJ: The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg. 206:2–7. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang X, Kanda T, Wu S, Nakamura M, Miyamura T, Nakamoto S, Banerjee A and Yokosuka O: Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World J Gastroenterol. 20:7197–7206. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12:2012010. View Article : Google Scholar : PubMed/NCBI | |
|
Sakurai M, Masuda M, Miki Y, Hirakawa H, Suzuki T and Sasano H: Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients. Int J Biol Markers. 30:e190–e199. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I, Figueroa A, Antón-Aparicio LM and Valladares-Ayerbes M: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 15:2972015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K, et al: miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 433:207–212. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai L, Zhang J, Ma DM, Li Y and Song FZ: MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumour Biol. 36:2875–2883. 2015. View Article : Google Scholar | |
|
Song L, Liu D, Wang B, He J, Zhang S, Dai Z, Ma X and Wang X: miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway. Oncol Rep. 34:525–531. 2015.PubMed/NCBI | |
|
Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H, Zhang S, Hong R and Gu X: The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Tumour Biol. 36:7185–7194. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Mao Q, Liu Y, Hao X, Zhang S and Zhang J: Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res. 25:46–54. 2013.PubMed/NCBI | |
|
Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching PA, et al: Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Res Treat. 147:61–68. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Wang X, Shen H, Deng R and Xue K: Combination of mir-21 with circulating tumor cells markers improve diagnostic specificity of metastatic breast cancer. Cell Biochem Biophys. 73:87–91. 2015. View Article : Google Scholar | |
|
Han X, Yan S, Weijie Z, Feng W, Liuxing W, Mengquan L and Qingxia F: Critical role of miR-10b in transforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer. Cancer Gene Ther. 21:60–67. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T and Sartorelli V: Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. 32:1607–1614. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Han G, Fan M and Zhang X: microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun. 456:804–809. 2015. View Article : Google Scholar | |
|
Dong Y, Zou J, Su S, Huang H, Deng Y, Wang B and Li W: MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. Mol Med Rep. 12:1016–1022. 2015.PubMed/NCBI | |
|
Zhang Y, Han D, Wei W, Cao W, Zhang R, Dong Q, Zhang J, Wang Y and Liu N: MiR-218 inhibited growth and metabolism of human glioblastoma cells by directly targeting E2F2. Cell Mol Neurobiol. 35:1165–1173. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 61:1075–1082. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Peng RQ, Wan HY, Li HF, Liu M, Li X and Tang H: MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem. 287:14301–14309. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY and Sun BC: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol. 43:632–641. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang XJ, Ye H, Zeng CW, He B, Zhang H and Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol. 3:462010. View Article : Google Scholar : PubMed/NCBI | |
|
Duan Q, Wang X, Gong W, Ni L, Chen C, He X, Chen F, Yang L, Wang P and Wang DW: ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One. 7:e315182012. View Article : Google Scholar : PubMed/NCBI | |
|
Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC and Hsieh SY: MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 57:584–591. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama K, Seki N, et al: miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 39:13–21. 2011.PubMed/NCBI | |
|
Cheng Y, Yang X, Deng X, Zhang X, Li P, Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1. Tumour Biol. 36:8015–8023. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H, Du L and Wang C: MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One. 10:e01180862015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang LL, Guo YJ, Zhao CN and Gao JY: Effects and mechanism of miR-214 on hepatocellular carcinoma. Asian Pac J Trop Med. 8:392–398. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z and Jiang J: MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun. 428:525–531. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yamane K, Jinnin M, Etoh T, Kobayashi Y, Shimozono N, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, et al: Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med Berl. 91:69–81. 2013. View Article : Google Scholar | |
|
Wen Z, Lei Z, Jin-An M, Xue-Zhen L, Xing-Nan Z and Xiu-Wen D: The inhibitory role of miR-214 in cervical cancer cells through directly targeting mitochondrial transcription factor A (TFAM). Eur J Gynaecol Oncol. 35:676–682. 2014. | |
|
Long LM, He BF, Huang GQ, Guo YH, Liu YS and Huo JR: microRNA-214 functions as a tumor suppressor in human colon cancer via the suppression of ADP-ribosylation factor-like protein 2. Oncol Lett. 9:645–650. 2015.PubMed/NCBI | |
|
Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X, Bai X, Sun Y, Zhang X, Sun H, et al: miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression. Tumour Biol. Sep 26–2015.Epub ahead of print. | |
|
Cao Q, Dong P and Wang Y, Zhang J, Shi X and Wang Y: miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D. Oncol Rep. 33:2606–2612. 2015.PubMed/NCBI | |
|
Jun GJ, Zhong GG and Ming ZS: miR-218 inhibits the proliferation of glioma U87 cells through the inactivation of the CDK6/cyclin D1/p21Cip1/Waf1 pathway. Oncol Lett. 9:2743–2749. 2015.PubMed/NCBI | |
|
Wang T, Chen T, Niu H, Li C, Xu C, Li Y, Huang R, Zhao J and Wu S: MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1. Int J Mol Med. 36:93–102. 2015.PubMed/NCBI | |
|
Heishima K, Mori T, Sakai H, Sugito N, Murakami M, Yamada N, Akao Y and Maruo K: MicroRNA-214 promotes apoptosis in canine hemangiosarcoma by targeting the COP1-p53 axis. PLoS One. 10:e01373612015. View Article : Google Scholar : PubMed/NCBI | |
|
Phatak P, Byrnes KA, Mansour D, Liu L, Cao S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. Oncogene. View Article : Google Scholar : Epub ahead of print. | |
|
Li PL, Zhang X, Wang LL, Du LT, Yang YM, Li J and Wang CX: MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis. 36:1484–1493. 2015.PubMed/NCBI | |
|
He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H and Zhang X: MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol. 36:2065–2075. 2015. View Article : Google Scholar | |
|
Xia H, Yan Y, Hu M, Wang Y, Wang Y, Dai Y, Chen J, Di G, Chen X and Jiang X: MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity. Neuro Oncol. 15:413–422. 2013. View Article : Google Scholar : | |
|
Jin Y, Yang CJ, Xu X, Cao JN, Feng QT and Yang J: MiR-214 regulates the pathogenesis of patients with coronary artery disease by targeting VEGF. Mol Cell Biochem. 402:111–122. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B and Song ZS: MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int. 13:682013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Xu Y, Long J, Guo K, Ge C and Du R: microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J Cancer Res. 27:247–257. 2015.PubMed/NCBI | |
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jin J, Cai L, Liu ZM and Zhou XS: miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TS, Lin JJ, Huo YN and Lee WS: Progesterone inhibits endothelial cell migration through suppression of the rho activity mediated by cSrc activation. J Cell Biochem. 116:1411–1418. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
van der Horst PH, Wang Y, Vandenput I, Kühne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger CW and Blok LJ: Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One. 7:e308402012. View Article : Google Scholar : PubMed/NCBI | |
|
Bokhari AA, Lee LR, Raboteau D, Hamilton CA, Maxwell GL, Rodriguez GC and Syed V: Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGFβ pathway. Cancer Prev Res (Phila). 7:1045–1055. 2014. View Article : Google Scholar | |
|
Xie M, Zhou L, Chen X, Gainey LO, Xiao J, Nanes MS, Hou A, You S and Chen Q: Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells. BioMed Res Int. 2015:4264292015. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M and Dong X: Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One. 9:e927142014. View Article : Google Scholar : PubMed/NCBI |
